Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience

Ueda Y, Kobayashi T, Ikegami T, et al. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience. J Gastroenterol. 2019;54(7):660-666.

Publication Type:

Journal Article

Authors:

Ueda, Y; Kobayashi, T; Ikegami, T; et, al

Source:

J Gastroenterol, Volume 54, Issue 7, p.660-666 (2019)

Cited On:

Patients Who Develop Recurrent HCV Infection Post Liver Transplantation

Export Citation:

RIS Format

Top